Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma

Introduction: Atezolizumab and bevacizumab (Ate/Bev) combination has become the new first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). Although several studies reported thyroid dysfunction after treatment with immune checkpoint inhibitors, the clinical and immunological sig...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Young Shin Song, Hannah Yang, Beodeul Kang, Jaekyung Cheon, Ilhwan Kim, Hyeyeong Kim, Won Suk Lee, Yun Beom Sang, Sanghoon Jung, Ho Yeong Lim, Vincent E. Gaillard, Chan Kim, Hong Jae Chon
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Karger Publishers 2023-05-01
סדרה:	Liver Cancer
נושאים:	hepatocellular carcinoma thyroid adverse events atezolizumab bevacizumab
גישה מקוונת:	https://beta.karger.com/Article/FullText/531182
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!